PMID- 34515066
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1421-9794 (Electronic)
IS  - 0009-3157 (Linking)
VI  - 66
IP  - 4
DP  - 2021
TI  - Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based 
      Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of 
      Randomized Controlled Trials.
PG  - 113-123
LID - 10.1159/000517990 [doi]
AB  - BACKGROUND: Whether topotecan plus platinum-based chemotherapy (TP) can achieve 
      better results than etoposide plus platinum-based chemotherapy (EP) for 
      small-cell lung cancer (SCLC) treatment is still controversial in clinical 
      applications. We compared the effectiveness and toxicity of TP versus EP in this 
      meta-analysis. METHODS: We searched PubMed, ScienceDirect, Cochrane Library, 
      Scopus, Ovid MEDLINE, Embase, Web of Science, and Google Scholar databases for 
      completeness one by one to find articles that met the conditions. Overall 
      survival (OS) and progression-free survival (PFS) were analyzed as primary 
      endpoints, and the objective response rate (ORR), disease control rate (DCR), and 
      adverse events (AEs) were analyzed as secondary endpoints. RESULTS: In total, 
      2,480 articles were retrieved, and 6 randomized controlled trials (RCTs) 
      contained results based on 1,924 patients. EP suggested conspicuously better OS 
      (hazard ratio [HR]: 1.24 [1.02, 1.50], p = 0.03) and PFS (HR: 1.39 [1.17, 1.64], 
      p = 0.0001) in SCLC treatment than TP, and ORR (54.1% vs. 60.2%, risk ratio [RR]: 
      0.77 [0.57, 1.06], p = 0.11), and DCR (74.9% vs. 84.4%, RR: 0.89 [0.79, 1.00], p 
      = 0.06) tended to favor EP. Subgroup analysis of subsistence showed that EP had 
      prominent benefit in the following subgroups: Asian, median age > 60, first-line 
      treatment, ECOG 0-2, intravenous topotecan, and cisplatin. AEs illustrated that 
      EP had conspicuously more anemia and alopecia than TP. CONCLUSIONS: Compared with 
      TP, EP was noticeably better in OS and PFS, but EP was toxic in terms of anemia 
      and alopecia. More multicenter, better planned RCTs are needed.
CI  - (c) 2021 S. Karger AG, Basel.
FAU - He, Mengyu
AU  - He M
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Wu, Bingxuan
AU  - Wu B
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Liu, Qiangyun
AU  - Liu Q
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Fang, Zige
AU  - Fang Z
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Liu, Miaowen
AU  - Liu M
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Yi, Fengming
AU  - Yi F
AD  - Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Wei, Yiping
AU  - Wei Y
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Peng, Jinhua
AU  - Peng J
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210819
PL  - Switzerland
TA  - Chemotherapy
JT  - Chemotherapy
JID - 0144731
RN  - 0 (Coordination Complexes)
RN  - 49DFR088MY (Platinum)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 7M7YKX2N15 (Topotecan)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Coordination Complexes/administration & dosage
MH  - Etoposide/*administration & dosage
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality
MH  - Platinum/*chemistry
MH  - Randomized Controlled Trials as Topic
MH  - Small Cell Lung Carcinoma/*drug therapy/mortality
MH  - Topotecan/*administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Etoposide
OT  - Meta-analysis
OT  - Platinum-based chemotherapy
OT  - Small-cell lung cancer
OT  - Topotecan
EDAT- 2021/09/14 06:00
MHDA- 2021/11/25 06:00
CRDT- 2021/09/13 09:07
PHST- 2021/04/13 00:00 [received]
PHST- 2021/06/19 00:00 [accepted]
PHST- 2021/09/14 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2021/09/13 09:07 [entrez]
AID - 000517990 [pii]
AID - 10.1159/000517990 [doi]
PST - ppublish
SO  - Chemotherapy. 2021;66(4):113-123. doi: 10.1159/000517990. Epub 2021 Aug 19.